

Pablo M Rusjan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7216927/publications.pdf>

Version: 2024-02-01

126
papers

8,466
citations

34105

52
h-index

48315

88
g-index

134
all docs

134
docs citations

134
times ranked

8825
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Translocator Protein Density, a Marker of Neuroinflammation, in the Brain During Major Depressive Episodes. <i>JAMA Psychiatry</i> , 2015, 72, 268.	11.0	700
2	Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [¹¹ C]raclopride PET study. <i>Brain</i> , 2009, 132, 1376-1385.	7.6	475
3	Increased Stress-Induced Dopamine Release in Psychosis. <i>Biological Psychiatry</i> , 2012, 71, 561-567.	1.3	222
4	Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 416-21.	4.5	220
5	Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. <i>Lancet Psychiatry</i> , 2018, 5, 339-347.	7.4	192
6	Optimal transcranial magnetic stimulation coil placement for targeting the dorsolateral prefrontal cortex using novel magnetic resonance image-guided neuronavigation. <i>Human Brain Mapping</i> , 2010, 31, 1643-1652.	3.6	188
7	Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2007, 14, 523-528.	3.3	182
8	Elevated Brain Monoamine Oxidase A Binding in the Early Postpartum Period. <i>Archives of General Psychiatry</i> , 2010, 67, 468.	12.3	177
9	The D _{2/3} dopamine receptor in pathological gambling: a positron emission tomography study with [¹¹ C]-(+)-propylhexahydro-naphtho-oxazin and [¹¹ C]raclopride. <i>Addiction</i> , 2013, 108, 953-963.	3.3	167
10	Brain Monoamine Oxidase A Binding in Major Depressive Disorder. <i>Archives of General Psychiatry</i> , 2009, 66, 1304.	12.3	166
11	Imaging Neuroinflammation in Gray and White Matter in Schizophrenia: An In-Vivo PET Study With [¹⁸ F]-FEPPA. <i>Schizophrenia Bulletin</i> , 2015, 41, 85-93.	4.3	158
12	Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [¹¹ C]DASB. <i>Movement Disorders</i> , 2008, 23, 1776-1780.	3.9	155
13	Higher Binding of the Dopamine D ₃ Receptor-Preferring Ligand [¹¹ C]-(+)-Propyl-Hexahydro-Naphtho-Oxazin in Methamphetamine Polydrug Users: A Positron Emission Tomography Study. <i>Journal of Neuroscience</i> , 2012, 32, 1353-1359.	3.6	152
14	An automated method for the extraction of regional data from PET images. <i>Psychiatry Research - Neuroimaging</i> , 2006, 147, 79-89.	1.8	148
15	Adverse Subjective Experience With Antipsychotics and Its Relationship to Striatal and Extrastriatal D ₂ Receptors: a PET Study in Schizophrenia. <i>American Journal of Psychiatry</i> , 2007, 164, 630-637.	7.2	141
16	Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[¹¹ C]DASB and structural brain imaging study. <i>Brain</i> , 2010, 133, 1779-1797.	7.6	134
17	Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 833.	11.0	132
18	Translocator Protein (18 kDa) Polymorphism (rs6971) Explains <i>in-vivo</i> Brain Binding Affinity of the PET Radioligand [¹⁸ F]-FEPPA. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 968-972.	4.3	131

#	ARTICLE	IF	CITATIONS
19	Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. <i>Brain</i> , 2014, 137, 565-575.	7.6	116
20	First Human Evidence of d-Amphetamine Induced Displacement of a D2/3 Agonist Radioligand: A [11C]-(+)-PHNO Positron Emission Tomography Study. <i>Neuropsychopharmacology</i> , 2008, 33, 279-289.	5.4	109
21	The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [11C]-(+)-PHNO PET Study. <i>Neuropsychopharmacology</i> , 2009, 34, 1078-1086.	5.4	109
22	Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [¹⁸ F]FEPPA. <i>American Journal of Psychiatry</i> , 2017, 174, 118-124.	7.2	103
23	Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data. <i>Biological Psychiatry</i> , 2018, 84, 433-442.	1.3	103
24	In-vivo imaging of grey and white matter neuroinflammation in Alzheimer's disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA. <i>Molecular Psychiatry</i> , 2015, 20, 1579-1587.	7.9	101
25	Heightened D3 Dopamine Receptor Levels in Cocaine Dependence and Contributions to the Addiction Behavioral Phenotype: A Positron Emission Tomography Study with [11C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2014, 39, 311-318.	5.4	99
26	Potential of Gamma Oscillatory Activity through Repetitive Transcranial Magnetic Stimulation of the Dorsolateral Prefrontal Cortex. <i>Neuropsychopharmacology</i> , 2009, 34, 2359-2367.	5.4	98
27	Quantitation of Translocator Protein Binding in Human Brain with the Novel Radioligand [¹⁸ F]-FEPPA and Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 1807-1816.	4.3	98
28	The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors. <i>Archives of General Psychiatry</i> , 2009, 66, 606.	12.3	97
29	Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. <i>Human Brain Mapping</i> , 2008, 29, 400-410.	3.6	95
30	Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0138721.	2.5	95
31	Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. <i>Brain</i> , 2009, 132, 1366-1375.	7.6	93
32	Saliency network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. <i>Annals of Neurology</i> , 2015, 77, 269-280.	5.3	93
33	Extrastriatal dopaminergic dysfunction in tourette syndrome. <i>Annals of Neurology</i> , 2010, 67, 170-181.	5.3	92
34	Investing in the Future: Stimulation of the Medial Prefrontal Cortex Reduces Discounting of Delayed Rewards. <i>Neuropsychopharmacology</i> , 2015, 40, 546-553.	5.4	89
35	Positron Emission Tomography Quantification of [11C]-(+)-PHNO Binding in the Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 857-871.	4.3	88
36	Microglial activation in Parkinson's disease using [18F]-FEPPA. <i>Journal of Neuroinflammation</i> , 2017, 14, 8.	7.2	88

#	ARTICLE	IF	CITATIONS
37	Increased Vesicular Monoamine Transporter Binding during Early Abstinence In Human Methamphetamine Users: Is VMAT2 a Stable Dopamine Neuron Biomarker?. <i>Journal of Neuroscience</i> , 2008, 28, 9850-9856.	3.6	86
38	Stress-Induced Dopamine Response in Subjects at Clinical High Risk for Schizophrenia with and without Concurrent Cannabis Use. <i>Neuropsychopharmacology</i> , 2014, 39, 1479-1489.	5.4	86
39	Kinetic Modeling of the Monoamine Oxidase B Radioligand [¹¹ C]SL25.1188 in Human Brain with High-Resolution Positron Emission Tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 883-889.	4.3	83
40	Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. <i>Schizophrenia Research</i> , 2011, 131, 63-68.	2.0	78
41	Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 634.	11.0	74
42	Monoamine Oxidase A Binding in the Prefrontal and Anterior Cingulate Cortices During Acute Withdrawal From Heavy Cigarette Smoking. <i>Archives of General Psychiatry</i> , 2011, 68, 817.	12.3	67
43	Relationship of Monoamine Oxidase-A Distribution Volume to Postpartum Depression and Postpartum Crying. <i>Neuropsychopharmacology</i> , 2015, 40, 429-435.	5.4	67
44	Mapping Human Brain Fatty Acid Amide Hydrolase Activity with PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 407-414.	4.3	65
45	[¹¹ C]â€(+)-â€PHNO PET imaging of dopamine D _{2/3} receptors in Parkinson's disease with impulse control disorders. <i>Movement Disorders</i> , 2015, 30, 160-166.	3.9	65
46	Heightened Dopaminergic Response to Amphetamine at the D3 Dopamine Receptor in Methamphetamine Users. <i>Neuropsychopharmacology</i> , 2016, 41, 2994-3002.	5.4	62
47	Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. <i>Psychopharmacology</i> , 2007, 193, 539-545.	3.1	61
48	Increased dopamine release in the right anterior cingulate cortex during the performance of a sorting task: A [11C]FLB 457 PET study. <i>NeuroImage</i> , 2009, 46, 516-521.	4.2	60
49	Greater Monoamine Oxidase A Binding in Perimenopausal Age as Measured With Carbon 11â€Labeled Harmine Positron Emission Tomography. <i>JAMA Psychiatry</i> , 2014, 71, 873.	11.0	58
50	The Fatty Acid Amide Hydrolase C385A Variant Affects Brain Binding of the Positron Emission Tomography Tracer [¹¹ C]CURB. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1237-1240.	4.3	58
51	Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18kDa (TSPO) radioligand, [18F]-FEPPA. <i>NeuroImage</i> , 2014, 84, 868-875.	4.2	56
52	Elevation of Dopamine Induced by Cigarette Smoking: Novel Insights from a [11C]-(+)-PHNO PET Study in Humans. <i>Neuropsychopharmacology</i> , 2014, 39, 415-424.	5.4	54
53	Elevated Monoamine Oxidase A Binding During Major Depressive Episodes Is Associated with Greater Severity and Reversed Neurovegetative Symptoms. <i>Neuropsychopharmacology</i> , 2014, 39, 973-980.	5.4	53
54	Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB. <i>Biological Psychiatry</i> , 2016, 80, 691-701.	1.3	53

#	ARTICLE	IF	CITATIONS
55	The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 715.	2.1	52
56	Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease. <i>Human Brain Mapping</i> , 2013, 34, 1591-1604.	3.6	52
57	Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [¹¹ C]-harmine PET study. <i>Journal of Psychiatry and Neuroscience</i> , 2011, 36, 375-382.	2.4	49
58	D ₃ dopamine receptor-preferring [¹¹ C]-PHNO PET imaging in Parkinson patients with dyskinesia. <i>Neurology</i> , 2016, 86, 224-230.	1.1	49
59	Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3150-3160.	4.3	48
60	Imaging Microglial Activation in Individuals at Clinical High Risk for Psychosis: an In Vivo PET Study with [¹⁸ F]FEPPA. <i>Neuropsychopharmacology</i> , 2017, 42, 2474-2481.	5.4	47
61	A Positron Emission Tomography Study of 5-Hydroxytryptamine-1A Receptors in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 888-898.	1.2	45
62	Dopamine Response to Psychosocial Stress in Chronic Cannabis Users: A PET Study With [¹¹ C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2013, 38, 673-682.	5.4	45
63	Evaluating the Relationship between Long Interval Cortical Inhibition, Working Memory and Gamma Band Activity in the Dorsolateral Prefrontal Cortex. <i>Clinical EEG and Neuroscience</i> , 2008, 39, 150-155.	1.7	44
64	Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw181.	4.3	44
65	Relationship of monoamine oxidase A binding to adaptive and maladaptive personality traits. <i>Psychological Medicine</i> , 2011, 41, 1051-1060.	4.5	43
66	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease. <i>Brain</i> , 2017, 140, 1371-1383.	7.6	41
67	Impaired Prefrontal Cortical Dopamine Release in Schizophrenia During a Cognitive Task: A [¹¹ C]-FLB 457 Positron Emission Tomography Study. <i>Schizophrenia Bulletin</i> , 2019, 45, 670-679.	4.3	39
68	Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naïve patients and healthy controls while performing a cognitive task. <i>Journal of Psychiatry and Neuroscience</i> , 2013, 38, 98-106.	2.4	36
69	[¹⁸ F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. <i>Brain Structure and Function</i> , 2018, 223, 589-595.	2.3	36
70	Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient-Control Differences. <i>Biological Psychiatry</i> , 2021, 89, e5-e8.	1.3	36
71	In Vivo Imaging of Translocator Protein in Long-term Cannabis Users. <i>JAMA Psychiatry</i> , 2019, 76, 1305.	11.0	34
72	Serotonin-1A receptors in frontotemporal dementia compared with controls. <i>Psychiatry Research - Neuroimaging</i> , 2007, 156, 247-250.	1.8	33

#	ARTICLE	IF	CITATIONS
73	Cortical stress regulation is disrupted in schizophrenia but not in clinical high risk for psychosis. <i>Brain</i> , 2018, 141, 2213-2224.	7.6	32
74	Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder. <i>Biological Psychiatry</i> , 2020, 88, 649-656.	1.3	32
75	Serotonin transporter binding is reduced in seasonal affective disorder following light therapy. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 410-419.	4.5	30
76	Convergent Effects of Acute Stress and Glucocorticoid Exposure upon MAO-A in Humans. <i>Journal of Neuroscience</i> , 2012, 32, 17120-17127.	3.6	29
77	Imaging microglial activation and amyloid burden in amnesic mild cognitive impairment. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 1885-1895.	4.3	29
78	Blocking of Fatty Acid Amide Hydrolase Activity with PF-04457845 in Human Brain: A Positron Emission Tomography Study with the Novel Radioligand [¹¹ C]CURB. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1827-1835.	4.3	28
79	Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB. <i>Neuropsychopharmacology</i> , 2020, 45, 1289-1296.	5.4	28
80	Serotonin Transporter Occupancy and the Functional Neuroanatomic Effects of Citalopram in Geriatric Depression. <i>American Journal of Geriatric Psychiatry</i> , 2011, 19, 1016-1025.	1.2	27
81	Dynamic, Adaptive Changes in MAO-A Binding after Alterations in Substrate Availability: An <i>in vivo</i> [¹¹ C]-Harmine Positron Emission Tomography Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 443-446.	4.3	27
82	Monoamine Oxidase-A Occupancy by Moclobemide and Phenzelzine: Implications for the Development of Monoamine Oxidase Inhibitors. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv078.	2.1	27
83	Dopamine response to psychosocial stress in humans and its relationship to individual differences in personality traits. <i>Journal of Psychiatric Research</i> , 2012, 46, 890-897.	3.1	26
84	Nigral Stress-Induced Dopamine Release in Clinical High Risk and Antipsychotic-Naïve Schizophrenia. <i>Schizophrenia Bulletin</i> , 2018, 44, 542-551.	4.3	26
85	GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 111-119.	2.4	26
86	On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study. <i>Translational Psychiatry</i> , 2020, 10, 2.	4.8	25
87	Light therapy and serotonin transporter binding in the anterior cingulate and prefrontal cortex. <i>Acta Psychiatrica Scandinavica</i> , 2015, 132, 379-388.	4.5	24
88	Whole Body Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, [18F]-FEPPA, to Image Translocator Protein (18kDa). <i>Molecular Imaging and Biology</i> , 2013, 15, 353-359.	2.6	23
89	The Relationship Between Serotonin 2A Receptor and Cognitive Functions in Nondemented Parkinson's Disease Patients with Visual Hallucinations. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 698-709.	1.5	23
90	The Interaction Between Neuroinflammation and β^2 -Amyloid in Cognitive Decline in Parkinson's Disease. <i>Molecular Neurobiology</i> , 2020, 57, 492-501.	4.0	23

#	ARTICLE	IF	CITATIONS
91	Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [¹¹ C]CURB positron emission tomography study. <i>Neuropsychopharmacology</i> , 2020, 45, 1834-1841.	5.4	23
92	Interaction between TSPO "a neuroimmune marker" and redox status in clinical high risk for psychosis: a PET "MRS study. <i>Neuropsychopharmacology</i> , 2018, 43, 1700-1705.	5.4	22
93	Greater Monoamine Oxidase A Binding in Alcohol Dependence. <i>Biological Psychiatry</i> , 2014, 75, 756-764.	1.3	21
94	Fatty acid amide hydrolase is lower in young cannabis users. <i>Addiction Biology</i> , 2021, 26, e12872.	2.6	21
95	Replicating predictive serum correlates of greater translocator protein distribution volume in brain. <i>Neuropsychopharmacology</i> , 2020, 45, 925-931.	5.4	20
96	Feasibility study of TSPO quantification with [¹⁸ F]FEPPA using population-based input function. <i>PLoS ONE</i> , 2017, 12, e0177785.	2.5	20
97	Influence of a low dose of amphetamine on vesicular monoamine transporter binding: A PET (+)[¹¹ C]DTBZ study in humans. <i>Synapse</i> , 2010, 64, 417-420.	1.2	19
98	Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis. <i>Biological Psychiatry</i> , 2020, 88, 727-735.	1.3	18
99	Quantitative imaging of neuroinflammation in human white matter: A positron emission tomography study with translocator protein 18 kDa radioligand, [¹⁸ F]FEPPA. <i>Synapse</i> , 2014, 68, 536-547.	1.2	17
100	Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [¹¹ C](+)-PHNO and [¹¹ C]raclopride positron emission tomography imaging study. <i>Human Brain Mapping</i> , 2015, 36, 2592-2601.	3.6	17
101	TSPO expression and brain structure in the psychosis spectrum. <i>Brain, Behavior, and Immunity</i> , 2018, 74, 79-85.	4.1	17
102	Whole-Body Radiation Dosimetry of ¹¹ C-Carbonyl-URB694: A PET Tracer for Fatty Acid Amide Hydrolase. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1993-1997.	5.0	15
103	Interaction of APOE4 alleles and PET tau imaging in former contact sport athletes. <i>NeuroImage: Clinical</i> , 2020, 26, 102212.	2.7	15
104	Exploring occupancy of the histamine H ₃ receptor by pitolisant in humans using PET. <i>British Journal of Pharmacology</i> , 2020, 177, 3464-3472.	5.4	15
105	Concentration, distribution, and influence of aging on the 18 kDa translocator protein in human brain: Implications for brain imaging studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1061-1076.	4.3	13
106	Lower amygdala fatty acid amide hydrolase in violent offenders with antisocial personality disorder: an [¹¹ C]CURB positron emission tomography study. <i>Translational Psychiatry</i> , 2021, 11, 57.	4.8	13
107	Genetically Predicted Brain C4A Expression Is Associated With TSPO and Hippocampal Morphology. <i>Biological Psychiatry</i> , 2021, 90, 652-660.	1.3	12
108	Presentation of Smoking-Associated Cues Does Not Elicit Dopamine Release after One-Hour Smoking Abstinence: A [¹¹ C](+)-PHNO PET Study. <i>PLoS ONE</i> , 2013, 8, e60382.	2.5	11

#	ARTICLE	IF	CITATIONS
109	Image Derived Input Function for [18F]-FEPPA: Application to Quantify Translocator Protein (18 kDa) in the Human Brain. PLoS ONE, 2014, 9, e115768.	2.5	11
110	Voxel-Based Imaging of Translocator Protein 18Kda (TSPO) in High-Resolution PET. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 348-350.	4.3	10
111	Inhibition of fatty acid amide hydrolase by BIA 10-2474 in rat brain. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3635-3639.	4.3	10
112	Microglia imaging in methamphetamine use disorder: a positron emission tomography study with the 18 kDa translocator protein radioligand [¹⁸ F]FEPPA. Addiction Biology, 2021, 26, e12876.	2.6	10
113	In vivo imaging translocator protein (TSPO) in autism spectrum disorder. Neuropsychopharmacology, 2022, 47, 1421-1427.	5.4	10
114	Stress-induced cortical dopamine response is altered in subjects at clinical high risk for psychosis using cannabis. Addiction Biology, 2020, 25, e12812.	2.6	9
115	A double-blind placebo-controlled trial of minocycline on translocator protein distribution volume in treatment-resistant major depressive disorder. Translational Psychiatry, 2021, 11, 334.	4.8	9
116	Preliminary data indicating a connection between stress-induced prefrontal dopamine release and hippocampal TSPO expression in the psychosis spectrum. Schizophrenia Research, 2019, 213, 80-86.	2.0	8
117	PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. Frontiers in Neurology, 2020, 11, 574.	2.4	7
118	DRD2 Genotype-Based Variants Modulates D2 Receptor Distribution in Ventral Striatum. Molecular Neurobiology, 2019, 56, 6512-6520.	4.0	6
119	Investigating the use of plasma pTau181 in retired contact sports athletes. Journal of Neurology, 2022, 269, 5582-5595.	3.6	4
120	Analysis of Variance in Neuroreceptor Ligand Imaging Studies. PLoS ONE, 2011, 6, e23298.	2.5	3
121	Voxel level quantification of [11C]CURB, a radioligand for Fatty Acid Amide Hydrolase, using high resolution positron emission tomography. PLoS ONE, 2018, 13, e0192410.	2.5	3
122	Prefrontal cortical dopamine release in clinical high risk for psychosis during a cognitive task: a [11C]FLB457 positron emission tomography study. European Neuropsychopharmacology, 2019, 29, 1023-1032.	0.7	2
123	Whole-Body Distribution and Radiation Dosimetry of ¹¹ C-(+)-PHNO, a D _{2/3} Agonist Ligand. Journal of Nuclear Medicine, 2012, 53, 1802-1806.	5.0	1
124	Personality traits in psychosis and psychosis risk linked to TSPO expression: a neuroimmune marker. Personality Neuroscience, 2020, 3, e14.	1.6	1
125	Parkinson's disease, impulse control disorder and the D3 dopamine receptor system: Preliminary PET imaging studies with [11C](+)-PHNO comparison with [11C]racloride. NeuroImage, 2010, 52, S84.	4.2	0
126	Quantification of translocator protein (18kDa) in the human brain with PET and a novel radioligand, [18F]-FEPPA. NeuroImage, 2010, 52, S134.	4.2	0